October 04, 2017, ALAMEDA, Calif. — AllCells, LLC, a leading provider of hematologic primary cell products for global life science research and further manufacturing of allogeneic cell therapy products is pleased to announce the successful deployment of its new Oracle enterprise resource planning (ERP) system, effective October 2. [Read more…]
$7.9M Granted to nTRACK Collaborative Project to Study Pluristem’s PLX-PAD Cells
- Grant from European Union’s Horizon 2020 program to nTRACK project designed to study nanoparticle effects on PLX-PAD cell viability and functionality
- Grant brings total to approximately $25 Million (€21.8 million) in funding from Horizon 2020 program to cover clinical and research activity for PLX-PAD
HAIFA, Israel, Oct. 02, 2017 — Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that a $7.9 million (€6.8 million) non-dilutive grant from the European Union’s Horizon 2020 program has been awarded to nTRACK, a collaborative project carried out by an international consortium led by LEITAT. [Read more…]
Will Glycostem Release 1st Allogeneic NK Cell Product with Off-the-Shelf Potential?
This interview comes shortly after Novartis became the first company to get a gene therapy approved in the United States, the CAR-T cell therapy, Kymriah®. The historic event demonstrates to investors, the public and funding providers alike that cell therapy is a sector that has emerged, no longer one that is evolving in the future. There are close to 40 companies developing redirected T cells or NK cells for therapeutic use. There are also 800+ cell therapy clinical trials underway around the world, and a considerable amount of research and preclinical work taking place across the cell therapy sector.
In the light of the recent Gilead takeover of Kite Pharma for $11 billion, the cellular immunotherapy sector is in focus among both investors and oncology and non-oncology companies. The search for the “next Kite” has begun!
Glycostem is a 10-year old clinical stage cellular immunotherapy company based in The Netherlands. The uniqueness around Glycostem, beyond that it is a privately funded company with strong phase I safety clinical trial data, is that it may become the first company with an allogeneic off-the- shelf product (oNKord®). This would potentially position NK cell technology to leapfrog CAR-T cell products, due to a safer profile, lower production costs, off-the- shelf status and positive clinical trial data. [Read more…]
VitaMine&Yours – Combining Private Health Care and Public Donation
Stem cells are a valuable resource for modern cell therapy. Newborn cord blood contains young, vital stem cells that can be obtained without invasive measures and are virtually free of any pathogens and environmental influences. These stem cell are cryogenically preserved in stem cell banks for decades and stored for medical health care.
Private stem cell banks store stem cells for a child and its family, with parents paying for this service. Public banks retain these stem cells for use by third-party recipients as a service for the general public. This service is funded by donations or public resources. Establishing a nationwide public donation system would be difficult and perhaps unfeasible due to costs, and based on a very high rejection rate of up to 80%, it would not make much sense, either.
Vita 34 in Germany, one of the ten most influential stem cell banks, has created a combination of both models. As part of this process, public registries will also have access to some of the privately stored cord blood. With VitaMine&Yours, Vita 34 has developed the first true hybrid product, combining private health care and public donation. [Read more…]
Genetically Modified Muscle Progenitor Cells with Stem Cell Medicine Ltd.
In the world of stem cells, there are a number of well-recognized market participants that receive a great deal of attention from the stem cell community.
At the same time, there are brilliant companies that quietly operate under the radar screen, building themselves up one intelligent and methodical step at a time. [Read more…]
- « Previous Page
- 1
- …
- 207
- 208
- 209
- 210
- 211
- …
- 313
- Next Page »